Chitkara Open Access Journals - Blog

Design, Synthesis and Antidiabetic Activity of Novel Sulfamoyl Benzamide Derivatives as Glucokinase Activators

Author(s):

  • Ajmer Singh Grewal and Sukhbir SinghChitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India
  • Kapil SharmaJan Nayak Ch. Devi Lal Memorial College of Pharmacy, Sirsa, 125055, Haryana, India
  • Vikramjeet SinghDepartment of Pharmaceutical Sciences, GJUS & T, Hisar, 125001, Haryana, India
  • Deepti PanditaAmity Institute of Molecular Medicine & Stem Cell Research, Amity University, Noida, 201303, Uttar Pradesh, India
  • Viney LatherAmity Institute of Pharmacy, Amity University, Noida, 201303, Uttar Pradesh, India

Keywords:

Antidiabetic activity, Benzamides, Diabetes mellitus, Glucokinase, GK activators, Molecular Docking

Abstract:

The present work has been planned to design, synthesize and evaluate the antidiabetic potential of a series of sulfamoyl benzamide derivatives as potential glucokinase (GK) activators. A new series of sulfamoyl benzamide derivatives was synthesized starting from 3-nitrobenzoic acid and characterized. In silico docking studies were performed to determine the binding interactions for the best fit conformations in the allosteric site of GK enzyme. Based on the results of in silico studies, the selected molecules were tested for their antidiabetic activity in animal studies (alloxan induced diabetic animal model). Compound 7 exhibited highest antidiabetic activity in animal studies. The results of in vivo antidiabetic activity studies were found to be in parallel to that of docking studies….

URL:

https://jptrm.chitkara.edu.in/index.php/jptrm/article/view/101/79

References:

Akinola, O., Gabriel, M., Suleiman, A., and Olorunsogbon, F. (2012). Treatment of alloxaninduced diabetic rats with metformin or glitazones is associated with amelioration of hyperglycaemia and neuroprotection. The Open Diabetes Journal, 5, 8–12. https://doi.org/10.2174/1876524601205010008

Bastaki, S. (2005). Diabetes mellitus and its treatment. International Journal of Diabetes Metabolism, 13, 111–134.

Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813–820. https://doi.org/10.1038/414813

Cade, W. T. (2008). Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical Therapy, 88, 1322–1335. https://doi.org/10.2522/ptj.20080008

Charaya N., Pandita D., Grewal A. S., and Lather V.(2018). Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Computational Biology and Chemistry, 73, 221–229. https://doi.org/10.1016/j.compbiolchem.2018.02.018

Cheruvallath, Z. S., Gwaltney, S. L., Sabat, M., Tang, M., Feng, J., Wang, H., et al. (2013). Design, synthesis and SAR of novel glucokinase activators. Bioorganic and Medicinal Chemistry Letters, 23(7), 2166–2171. https://doi.org/10.1016/j.bmcl.2013.01.093

Coghlan, M. and Leighton, B. (2008). Glucokinase activators in diabetes management. Expert Opinion on Investigational Drugs, 17(2), 145–167. https://doi.org/10.1517/13543784.17.2.145

Filipski, K. J., Guzman-Perez, A., Bian, J., Perreault, C., Aspnes, G. E., Didiuk, M. T., et al. (2013). Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. Bioorganic and Medicinal Chemistry Letters, 23(16), 4571–4578. https://doi.org/10.1016/j.bmcl.2013.06.036